Nauticus Robotics has secured a new customer, taking expanding its services to Brazil. Photo courtesy of Nauticus

Houston-based Nauticus Robotics, a developer of autonomous ocean robots, has landed a deal to supply its equipment to one of the world’s largest energy companies — a deal that eventually could blossom into $100 million worth of contracts.

Under the deal, Nauticus will dispatch its Aquanaut autonomous subsea robot to support offshore oil exploration activities carried out by Brazil’s Petrobras. Specifically, Aquanaut — propelled by artificial intelligence-enabled software — will supervise infield inspection services over a two-month span.

The deal with Brazil’s Petrobras represents Nauticus’ entry into the South American market and puts Nauticus in a position to score several Petrobras contracts that could collectively be valued at $100 million. Both companies are publicly traded.

Nicolaus Radford, founder and CEO of Nauticus, says Brazil offers a significant market opportunity for his company, as South America’s largest nation boasts one of the world’s most active offshore energy basins.

“A contract with [a] worldwide leading operator for Nauticus speaks to the state-of-the-art technologies of our autonomous robots as we further penetrate the global markets,” Radford says in a news release.

Petrobras is one of the world’s biggest offshore operators, managing 57 platforms, operating 10,000 miles of oil and gas pipelines, and producing the equivalent of 2.6 million barrels of oil per day. The company generated $124.47 billion in revenue last year.

Founded in 2014, Nauticus posted revenue of $11.4 million in 2022. The company went public last year through a $560 million merger with a special purpose acquisition company (SPAC). Nauticus recently opened a new office in The Ion, in addition to their Webster office.

“I see Nauticus being the preeminent ocean robotics company. I want Nauticus to be an empire. It starts small but it grows — and it grows in many different ways, and we’re exploring all of those different ways to grow,” Radford told InnovationMap in May. “We’re leading a technology renaissance in the marine space — and that happens only a few times in an industry.”

------

This article originally ran on EnergyCapital.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”

Chevron enters the lithium market with major Texas land acquisition

to market

Chevron U.S.A., a subsidiary of Houston-based energy company Chevron, has taken its first big step toward establishing a commercial-scale lithium business.

Chevron acquired leaseholds totaling about 125,000 acres in Northeast Texas and southwest Arkansas from TerraVolta Resources and East Texas Natural Resources. The acreage contains a high amount of lithium, which Chevron plans to extract from brines produced from the subsurface.

Lithium-ion batteries are used in an array of technologies, such as smartwatches, e-bikes, pacemakers, and batteries for electric vehicles, according to Chevron. The International Energy Agency estimates lithium demand could grow more than 400 percent by 2040.

“This acquisition represents a strategic investment to support energy manufacturing and expand U.S.-based critical mineral supplies,” Jeff Gustavson, president of Chevron New Energies, said in a news release. “Establishing domestic and resilient lithium supply chains is essential not only to maintaining U.S. energy leadership but also to meeting the growing demand from customers.”

Rania Yacoub, corporate business development manager at Chevron New Energies, said that amid heightening demand, lithium is “one of the world’s most sought-after natural resources.”

“Chevron is looking to help meet that demand and drive U.S. energy competitiveness by sourcing lithium domestically,” Yacoub said.

---

This article originally appeared on EnergyCapital.